874375-71-0

Upstream product

• 625128-15-6 methyl 1-phenylcyclopent-3-ene-1-carboxylate 
• 101-41-7 benzeneacetic acid methyl ester 
• 242482-24-2 methyl 2-phenyl-2-(prop-2-enyl)pent-4-enoate 

Downstream Products

• 874375-72-1 1-(((1-phenylcyclopent-3-enyl)methoxy)methyl)-3,5-bis(trifluoromethyl)benzene 
• 874375-73-2 3-((3,5-bis(trifluoromethyl)benzyloxy)methyl)-3-phenylcyclopentanol 
• 874375-74-3 3-((3,5-bis(trifluoromethyl)benzyloxy)methyl)-3-phenylcyclopentanone 
• 1429045-50-0 5-((3,5-bis(trifluoromethyl)benzyloxy)methyl)-5-phenylpiperidin-2-one 
• 1429045-44-2 4-((3,5-bis(trifluoro-methyl)benzyloxy)methyl)-4-phenylpiperidin-2-one 

Relevant academic research and scientific papers

Discovery of disubstituted piperidines and homopiperidines as potent dual NK1 receptor antagonists-serotonin reuptake transporter inhibitors for the treatment of depression

This report describes the synthesis, structure-activity relationships and activity of piperidine, homopiperidine, and azocane derivatives combining NK1 receptor (NK1R) antagonism and serotonin reuptake transporter (SERT) inhibition. Our studies culminated in the discovery of piperidine 2 and homopiperidine 8 as potent dual NK1R antagonists-SERT inhibitors. Compound 2 demonstrated significant activity in the gerbil forced swimming test, suggesting that dual NK1R antagonists-SERT inhibitors may be useful in treating depression disorders.

Copper-catalyzed desymmetrization of prochiral 4,4-disubstituted cyclopentenes: Via a site-selective allylic oxidation: A concise total synthesis of untenone A

The desymmetrization of prochiral 4,4-disubstituted cyclopentenes via a site-selective copper-catalyzed allylic oxidation is described. This study provides a direct comparison of a series of known methods for allylic oxidation, and thus identifies ligand-free copper(i) iodide as the optimal catalyst for this particular process. Notably, this work offers a convenient approach to the preparation of γ-quaternary α,β-unsaturated cyclopentenones, which permits an efficient three-step total synthesis of (±)-untenone A.

Cyclopentylamine and cyclohexylamine derivatives as NK-1/SSRI antagonists

The present disclosure relates to chemical compounds and their use in human therapy. A specific embodiment of the disclosure relates to compounds of Formula (I); or an isomer, a pharmaceutically acceptable salt or solvate thereof or a pharmaceutically acceptable formulation comprising said compounds are useful for the useful for the treatment or prevention of conditions mediated by tachykinins and/or selective inhibition of serotonin reuptake transporter protein. The compounds act as dual NK-1 antagonists and selective serotonin reuptake inhibitors.